Publication Information

Basic Information

Access and Citation

AI Researcher Chatbot

Get quick answers to your questions about the article from our AI researcher chatbot

Primary Location

Authors

Topics

Keywords

Related Works

Title: $Combined androgen blockade with bicalutamide for advanced prostate cancer
Abstract: Abstract BACKGROUND: A previously reported, double‐blind, randomized, multicenter phase 3 trial in 205 patients with stage C/D prostate cancer compared combined androgen blockade (CAB) with luteinizing hormone‐releasing hormone agonist (LHRH‐A) plus bicalutamide 80 mg versus LHRH‐A plus bicalutamide‐matching placebo (LHRH‐A monotherapy). The analysis at a median follow‐up of 2.4 years indicated that CAB significantly ( P < .001) prolonged the time to progression and the time to treatment failure. In the current report, survival data from a long‐term follow‐up (median, 5.2 years) were analyzed. METHODS: All deaths irrespective of cause and all prostate cancer‐specific deaths were recorded. The data were analyzed using Cox regression analysis and the log‐rank test. RESULTS: At a median follow‐up of 5.2 years, a significant overall survival advantage was observed in favor of CAB over LHRH‐A monotherapy (Cox regression analysis: hazard ratio, 0.78; 95% confidence interval, 0.60‐0.99; P = .0498; log‐rank test: P = .0425). The difference in cause‐specific survival between the 2 groups was not significant. The achievement of a prostate‐specific antigen (PSA) nadir concentration ≤1 ng/mL was a prognostic factor for improved survival. More patients attained PSA nadir concentrations ≤1 ng/mL with CAB compared with patients who received LHRH‐A monotherapy (81.4% vs 33.7%; P < .001). CONCLUSIONS: CAB with bicalutamide 80 mg offered a significant overall survival benefit compared with LHRH‐A monotherapy without reducing tolerability in patients with locally advanced or metastatic prostate cancer. Cancer 2009. © 2009 American Cancer Society.